Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia and lymphomas, gastrointestinal cancers, genitourinary cancers, lung cancer and multiple myeloma. Featuring perspectives from Drs Neeraj Agarwal, Tanios Bekaii-Saab, Kristen Ciombor, Brad Kahl, Mark Levis, Ann Partridge, Mark Pegram, Daniel Petrylak, Noopur Raje, David Sallman, Lecia Sequist, David Spigel, Saad Zafar Usmani and Andrew Zelenetz. Published November 23, 2021. (Webinar Audio Proceedings)
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue
Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Neeraj Agarwal, MD
Professor of Medicine
Senior Director for Clinical Research Innovation
Huntsman Cancer Institute Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah
Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Clovis Oncology, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc, Merck, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc.
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic in Arizona
Chair, ACCRU Research Consortium
Phoenix, Arizona
Advisory Committee: Immuneering Corporation, Imugene, Sun Biopharma; Consulting Agreements (to Institution): Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Foundation Medicine, Janssen Biotech Inc, Kanaph Therapeutics, Natera Inc, Sobi, Stemline Therapeutics Inc, Treos Bio, Xilis; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, FibroGen, Kintor, Lilly, Pancreatic Cancer Action Network; Inventions/Patents: WO/2018/183488, WO/2019/055687.
Kristen K Ciombor, MD, MSCI
Assistant Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Merck, Natera Inc, Pfizer Inc; Consulting Agreements: Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc.
Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri
Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Celgene Corporation, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc.
Mark Levis, MD, PhD
Professor of Oncology
Co-Division Director, Hematologic Malignancies
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
No relevant conflicts of interest to disclose.
Ann Partridge, MD, MPH
Vice Chair of Medical Oncology
Director, Program for Young Women with Breast Cancer
Director, Adult Survivorship Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Travel Support: Novartis.
Mark D Pegram, MD
Susy Yuan-Huey Hung Endowed Professor of Oncology
Director, Clinical and Translational Research Unit
Associate Dean for Clinical Research Quality
Stanford University School of Medicine
Associate Director for Clinical Research
Stanford Comprehensive Cancer Institute
Stanford, California
Advisory Committee: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Pfizer Inc, Sanofi Genzyme, Seagen Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Novartis, Pfizer Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
Dr Mark Pegram’s contribution to this publication was as a paid consultant and was not part of his Stanford University duties or responsibilities.
Daniel P Petrylak, MD
Professor of Internal Medicine (Medical Oncology) and Urology
Yale School of Medicine
New Haven, Connecticut
Consulting Agreements: Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc; Contracted Research: Gilead Sciences Inc.
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: Amgen Inc, bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, GlaxoSmithKline, Immuneel Therapeutics, Janssen Biotech Inc.
David Sallman, MD
Assistant Member
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida
Advisory Committee: AbbVie Inc, Aprea Therapeutics, Bristol-Myers Squibb Company, Intellia Therapeutics, Kite, A Gilead Company, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc; Consulting Agreements: Magenta Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Speakers Bureau: Bristol-Myers Squibb Company, Incyte Corporation, Servier Pharmaceuticals LLC.
Lecia V Sequist, MD, MPH
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital Cancer Center
The Landry Family Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.
David R Spigel, MD
Chief Scientific Officer
Thoracic Oncology
Sarah Cannon Research Institute
Nashville, Tennessee
Consulting Agreements (to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Curio Science, EMD Serono Inc, Evidera, Exelixis Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Intellisphere LLC, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Mirati Therapeutics, Molecular Templates, Novartis, Novocure Inc, Pfizer Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme; Contracted Research (to Institution): Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Denovo Biopharma, Eisai Inc, Elevation Oncology, EMD Serono Inc, Evelo Biosciences Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Grail Inc, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MacroGenics Inc, Merck, Molecular Partners, Molecular Templates, Nektar, Neon Therapeutics, Novartis, Novocure Inc, OncXerna Therapeutics Inc, Pfizer Inc, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, UT Southwestern Medical Center, Verastem Inc.
Saad Zafar Usmani, MD, MBA
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, New York
Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Mundipharma, Oncopeptides, Sanofi Genzyme, Seagen Inc, Secura Bio, SkylineDx, Takeda Pharmaceuticals USA Inc, TeneoBio; Contracted Research: Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Merck, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seagen Inc, SkylineDx, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Sanofi Genzyme.
Andrew D Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York
Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Cultura e Eventos LTDA, Curio Science, DAVA Oncology, Debiopharm, Gilead Sciences Inc, Instituto de Ciências Integradas, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, MEI Pharma Inc, MorphoSys, Oncopeptides, Ono Pharmaceutical Co Ltd, Quant Health, Sandoz Inc, a Novartis Division, Suzhou Liangyihui Network Technology Co Ltd, Vaniam Group, Verastem Inc; Contracted Research: AbbVie Inc, BeiGene Ltd, Genentech, a member of the Roche Group, Gilead Sciences Inc, MEI Pharma Inc, MethylGene Inc; Data and Safety Monitoring Board/Committee: BeiGene Ltd (DMC Chair), Bristol-Myers Squibb Company, Celgene Corporation, Juno Therapeutics, a Celgene Company; Scientific Advisory Board Chair: Lymphoma Research Foundation; Other: NCCN (B-Cell Lymphoma Panel Chair).
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Merck, Natera Inc, Novartis, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc and Sanofi Genzyme, Sanofi Genzyme, Seagen Inc, Taiho Oncology Inc and Takeda Pharmaceuticals USA Inc.
Release date: November 2021
Expiration date: November 2022
(WIFI is recommended for best performance):